Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial
Sean Wasserman, Angharad Davis, Cari Stek, Maxwell Chirehwa, Stephani Botha, Remy Daroowala, Marise Bremer, Mpumi Maxebengula, et al. (21 authors)
Antimicrobial Agents and Chemotherapy · 2021-05
Abstract
Higher doses of intravenous rifampicin may improve outcomes in tuberculous meningitis but are impractical in high-burden settings. We hypothesized that plasma rifampicin exposures would be similar between oral dosing of 35 mg/kg of body weight and intravenous dosing of 20 mg/kg, which has been proposed for efficacy trials in tuberculous meningitis.
MeSH terms
- Medicine
- Rifampicin
- Pharmacokinetics
- Dosing
- Tuberculous meningitis
- Interquartile range
- Confidence interval
- Meningitis
- Randomized controlled trial
- Internal medicine
- Gastroenterology
- Pharmacology